SCHEMBL20134779

SCHEMBL20134779

Cc1ccc(CC2CCN(C(=O)c3ccc(C4(C(C)C)NC(=O)NC4=O)cc3)CC2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.44
MEN1 O00255 4/20 0.44
GAA P10253 2/20 0.44
HTT P42858 2/20 0.44
LMNA P02545 2/20 0.44
ALDH1A1 P00352 1/20 0.44
CYP3A4 P08684 1/20 0.44
HPGD P15428 1/20 0.44
CYP2C19 P33261 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
CHRM2 P08172 2/20 0.42
CCR5 P51681 1/20 0.42
STAT3 P40763 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20134777 1.00 KMT2A (0.44) KMT2AMEN1GAAHTTLMNA
SCHEMBL20135716 0.85 KMT2A (0.61) KMT2AMEN1LMNAALDH1A1SMN1; SMN2
SCHEMBL20135714 0.85 KMT2A (0.61) KMT2AMEN1LMNAALDH1A1SMN1; SMN2
SCHEMBL20134899 0.83 KMT2A (0.46) KMT2AMEN1HTTLMNAALDH1A1
SCHEMBL20135456 0.82 ADAMTS5 (0.36) KMT2AMEN1GAAHTTLMNA
SCHEMBL20135459 0.82 ADAMTS5 (0.36) KMT2AMEN1GAAHTTLMNA
SCHEMBL20135100 0.79 CCNK (0.49)
SCHEMBL29688787 0.79 CCNK (0.49)
SCHEMBL20135102 0.79 CCNK (0.49)
SCHEMBL20791707 0.78 KMT2A (0.46) KMT2AMEN1GAALMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 KMT2A 2568/4885MEN1 3735/4885GAA 1697/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 KMT2A 2539/4885MEN1 2913/4885GAA 1645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.